Cidara Therapeutics (CDTX) has shared an announcement.
Cidara Therapeutics, Inc. stockholders convened for their 2024 Annual Meeting and cast decisive votes on several key proposals. They sanctioned the expansion of authorized common stock from 20 million to 50 million shares and endorsed the 2024 Equity Incentive Plan. Additionally, the election of three Class III Directors and the ratification of Ernst & Young LLP as the independent auditor for the upcoming fiscal year were affirmed. Shareholders also approved, in line with Nasdaq rules, a potential change of control due to the conversion of Series A Preferred Stock, as well as the compensation of executive officers and, if needed, the adjournment of the meeting to garner additional proxy votes.
Find detailed analytics on CDTX stock on TipRanks’ Stock Analysis page.
